Recent Updates
Recently added Catalysts
OSUR Positive Sentiment

OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th

Key Takeaway: OraSure Technologies, Inc. (NASDAQ: OSUR) is scheduled to announce its first quarter 2024 financial results during a conference call on May 8, 2024, at 4:45 p.m. ET. Investors can access the call via a webcast on the company's website, where it will be archived for approximately 90 days. This call aims to highlight both financial performance and key business developments, emphasizing the company's commitment to healthcare innovation.
Price reaction · baseline $5.28 (2024-04-19 close) · clean, no other OSUR news in the window
day 0 close · peak
+1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • OraSure will announce its first quarter 2024 financial results.
  • The earnings call allows direct engagement with investors.
  • The company is positioned to share key business developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~48 mo
Minimal dilution risk
Lead asset
1.0 cc HBVAXPRO 10mcgr/ml
Phase 1 · Hepatitis B

Full Press Release Details

BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2024 financial results and certain business developments for 4:45 p.m. ET on Wednesday, May 8, 2024.
A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended and will be available for approximately 90 days.
To participate in the live conference call, please follow the link below to pre-register. After registering, you will be provided with access details via email.
About OraSure Technologies, Inc.
OraSure Technologies (the “Company”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. The Company improves access, quality, and value of healthcare with innovation in effortless tests, sample management solutions, and services. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass diagnostics, tools, and services. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.
Investor Contact: Media Contact:
Jason Plagman Amy Koch
VP, Investor Relations Director, Corporate Communications
investorinfo@orasure.com media@orasure.com

Frequently Asked Questions

When is OraSure's first quarter earnings call scheduled?

OraSure's earnings call is set for 4:45 p.m. ET on May 8, 2024.

How can I access the earnings conference call?

You can access the call via the investor relations page on OraSure's website.

Will the conference call be archived?

Yes, the webcast will be archived and available for about 90 days post-call.

What does OraSure Technologies specialize in?

OraSure focuses on improving healthcare through innovative diagnostic tests and services.

Who can benefit from OraSure's products?

OraSure's products serve hospitals, clinics, labs, and consumers globally.

Last updated: Apr 22, 2024